Drug patch approved for advanced Parkinson's and restless leg syndrome

(HealthDay) -- The Neupro (rotigotine) transdermal system has been approved by the U.S. Food and Drug Administration to treat advanced Parkinson's disease and moderate-to-severe restless leg syndrome, the Belgian drug maker UCB said Tuesday in a news release.

The continuous drug delivery patch was first approved by the FDA in 2007 to treat early-stage Parkinson's.

The dopamine agonist skin patch is believed to work by stimulating within the caudate-putamen, the portion of the brain that regulates movement, the company said.

In clinical testing, observed side effects of Neupro included nausea, vomiting, skin site reactions, dizziness, insomnia and headache.

Neupro contains sodium metabisulfite, which could cause deadly allergic-like reactions in certain susceptible people. Also, the drug should not be used by pregnant women, UCB warned.

More information: To learn more about this medication, visit Medline Plus.

add to favorites email to friend print save as pdf

Related Stories

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

Recommended for you

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments